

Exhibit 99.1



**Alcon**<sup>®</sup>



## Third Quarter 2010 Webcast

October 21, 2010

# Safe Harbor Statement

*This presentation, made on October 21, 2010, includes forward-looking statements based on current expectations and Alcon does not undertake the obligation to update the forward-looking information or statements. These expectations could differ materially from actual results and are subject to a number of uncertainties and risks as detailed in the company's form 20-F filed with the SEC on March 16, 2010.*

*In addition, this presentation may include several financial measures, to assist in better understanding our business, that are not prepared in accordance with generally accepted accounting principles (GAAP). These non-GAAP financial measures will be reconciled at the end of this presentation or in associated public information filed with the SEC.*

*Reports noted above are available on our website at [www.alcon.com](http://www.alcon.com) in the "Investors and Media" section. For further information contact the Alcon Investor Relations Department at (817) 551-8805.*

# **Business Overview**

**Kevin Buehler**

**President and Chief Executive Officer**

# Strong, Consistent Performance

## Strong top-line sales growth

- Q3 2010 organic growth of 8.7% (+9.0% reported)
- YTD 2010 organic growth of 9.9% (+12.2% reported)

## Solid financial performance

- Operating income
  - Q3 2010 adjusted growth of 8.7% (-14.4% reported)
  - YTD 2010 adjusted growth of 15.7% (+10.2% reported)
- Net income
  - Q3 2010 adjusted growth of 8.5% (-13.4% reported)
  - YTD 2010 adjusted growth of 16.1% (+9.0% reported)


Organic sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years. Reconciliations for organic sales growth are provided at the end of this presentation.

Adjusted operating income and diluted EPS measure the results of the company's operations without certain items that pertain only to the period presented. Management believes these measures are an important measure of the company's operations because they provide investors with a clearer picture of the core operations of the company. These measures are considered non-GAAP financial measures as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.

# Delivering Sustainable Organic Growth

## Global Organic Sales Growth by Quarter

2010 Year-to-date organic growth of 9.9%  
(+12.2% reported)




Growth rates as compared to same period in prior year.

Organic sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years. Reconciliations for organic sales growth is provided at the end of this presentation.

# Balanced Global Contributions

## Q3 2010 Sales by Geography




Growth rates as compared to same period in prior year.

Organic sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years. Reconciliations for organic sales growth is provided at the end of this presentation.

# Diversified Product Growth

## Q3 Global Sales by Product Line



Growth rates as compared to same period in prior year.

Organic sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years. Reconciliations for organic sales growth are provided at the end of this presentation.

# Commercial Execution Driving Market Share Gains

<u>RX Growth</u>	Global August YTD		U.S. August YTD	
	Brand	Market	Brand	Market
TRAVATAN® Family	10.9%	6.7%	9.2%	2.9%
Azopt® + AZARGA®	16.5%	7.5%	7.9%	10.0%
Vigamox® *	10.1%	6.2%	-2.2%	-4.2%
NEVANAC®	39.5%	3.1%	14.9%	-0.4%
Patanol® + Pataday™	-1.7%	-9.6%	4.5%	3.3%
CIPRODEX® *	10.1%	10.2%	5.6%	3.3%

Source: Global-IMS\*\* U.S.-WK Health

\* Moxifloxacin, the active ingredient in **Vigamox®**, is licensed to Alcon by Bayer Schering Pharma. **CIPRODEX®** is a registered trademark of Bayer AG and licensed to Alcon by Bayer Schering Pharma.

\*\* Top 32 countries


**Alcon®**



# U.S. Cataract Procedure Growth Moderating

## U.S. Cataract Procedure Growth

Market Scope estimates full-year 2010 U.S. cataract procedures will rise 2.7%



Source: Market Scope


Growth rates as compared to same period in prior year.

**Alcon**<sup>®</sup>

# Increasing Penetration Key to AT-IOL Growth

## AT-IOLs as a Percentage of Total U.S. IOLs Implanted

Rising utilization of both presbyopia-correcting and toric lenses are driving U.S. AT-IOL penetration




Source: Market Scope

**Alcon**<sup>®</sup>

# Durable Opportunity in International Markets


## Developed International Organic Growth



**Reported Growth**

8.6%    19.9%    18.0%    3.7%    8.0%

## Emerging Market Organic Growth



21.0%    21.3%    21.5%    1.0%    24.3%

Growth rates as compared to same period in prior year.

Organic sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years. Reconciliations for organic sales growth are provided at the end of this presentation.

# 2010 Key Late Stage R&D Pipeline Activity

2010 SUBMISSIONS		2010 APPROVALS	
FILED	PENDING	RECEIVED	PENDING
ALLEGRETTO™ EX-500 refractive laser (EU)	AcrySof® IQ Toric expanded diopter range (Japan)	Patanase® new indication (US)	TRAVATAN® Alternative Preservative System (EU)
TRAVATAN® Alternative Preservative System (EU)	ALLEGRETTO™ EX-500 refractive laser (US)	ACRYCERT® C (US/EU)	Moxifloxacin new formulation (US)
Moxifloxacin new formulation (US)	Ex-PRESS® ophthalmic glaucoma device (Japan)	DuoTrav® Alternative Preservative System (Japan)	NEVANAC® (Japan)
WaveLight® FS-200 femtosecond laser (US/EU)	New MPDS (EU)	AcrySof® IQ ReSTOR® Toric (EU)	AcrySof® IQ ReSTOR® +3.0 (Japan)
ALLEGRETTO WAVE® Eye-Q 400 Hz laser (Japan)		7500 cpm UltraVit™ Probe (US/EU)	WaveLight® FS-200 femtosecond laser (US)
Systane® BALANCE (EU)		WaveLight® FS-200 femtosecond laser (EU)	
AcrySof® IQ Toric expanded diopter range (US/EU)		Systane® BALANCE (US)	
DuoTrav® Alternative Preservative System (EU)		AcrySof® IQ Toric expanded diopter range (EU)	
Pataday® (Japan)		ALLEGRETTO™ EX-500 refractive laser (EU)	
New MPDS (US)			

Indicates activity since Q2 earnings call

# Business Development Delivering Growth

## Optonol Acquisition

- Further broadens Alcon's extensive glaucoma product offering
- Sales of Ex-PRESS<sup>®</sup> ophthalmic glaucoma device steadily building


## DUREZOL<sup>®</sup> Acquisition

- Adds potent steroid to Alcon's anti-infective portfolio
- Integration exceeding expectations
  - Generating near-term sales momentum
  - 6.0% August 2010 U.S. market share vs. 1.3% August 2009

# Leveraging Commercial Capabilities

## DUREZOL® U.S. Market Share

August 2010 U.S. market share of 6.0%  
versus 1.3% in August 2009



Source: WK Health

**Alcon®**

# Exciting New Cataract Technology

## LenSx Lasers Acquisition

- LenSx femtosecond laser improves key steps in cataract surgery
  - Uses technology to automate previously manual procedures
  - Micron-level laser precision and predictability
- Provides new growth driver to Alcon's leading cataract portfolio
  - Complementary procedure to phacoemulsification
  - Represents incremental revenue opportunity
- Limited product introduction in late 2010, full launch in 2011

# Change of Majority Ownership

- Alcon remains an independent, publicly-traded company
- Potential opportunities to create value for Alcon
  - Within the framework of good corporate governance
  - Through arm's length negotiations
- Potential to leverage a leadership position in the total healthcare market
- Potential access to broad-based pharmaceutical research capability applicable to ophthalmology



# Financial Review

**Rick Croarkin**

**Senior Vice President, Finance and Chief Financial Officer**


# Sales

## Q3 Sales

*(dollars in millions)*

**+9.0% Reported**

**+8.7% Organic Growth**




## YTD Sales

*(dollars in millions)*

**+12.2% Reported**

**+9.9% Organic Growth**




Growth rates as compared to same period in prior year.

Organic sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years. Reconciliations for organic sales growth is provided at the end of this presentation.

# Gross Profit

## Q3 Gross Profit

*(dollars in millions)*



Growth rate as compared to same period in prior year.

# Change of Majority Ownership Expenses

	Q3 2010	YTD 2010
Other operating expenses	\$ 133	\$ 141
Tax effect	<u>(20)</u>	<u>(20)</u>
Impact to Net earnings	\$ 113	\$ 121
Impact to diluted EPS	\$ 0.37	\$ 0.40


*(dollars in millions, except per share amounts)*

Adjusted operating income, net income and diluted EPS measure the results of the company's operations without certain items that pertain only to the period presented. Management believes these measures are an important measure of the company's operations because they provide investors with a clearer picture of the core operations of the company. These measures are considered non-GAAP financial measures as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.

# Operating Income

## Q3 Reported

*(dollars in millions)*




**% of  
Sales**

**35.8%**

**28.1%**

## Q3 Adjusted

*(dollars in millions)*



**% of  
Sales**

**35.8%**


**35.7%**

Growth rates as compared to same period in prior year.

Adjusted operating income measures the results of the company's operations without certain items that pertain only to the period presented. Management believes this measure is an important measure of the company's operations because it provides investors with a clearer picture of the core operations of the company. This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.

**Alcon**<sup>®</sup>

# Operating Income




Growth rates as compared to same period in prior year.


Adjusted operating income measures the results of the company's operations without certain items that pertain only to the period presented. Management believes this measure is an important measure of the company's operations because it provides investors with a clearer picture of the core operations of the company. This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.

# Net Earnings and Diluted EPS

## Q3 Reported Net Earnings



## Q3 Adjusted Net Earnings




Growth rates as compared to same period in prior year.

Adjusted operating income measures the results of the company's operations without certain items that pertain only to the period presented. Management believes this measure is an important measure of the company's operations because it provides investors with a clearer picture of the core operations of the company. This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.

# Net Earnings and Diluted EPS

## YTD Reported Net Earnings




% of  
Sales

32.4%

31.5%

## YTD Adjusted Net Earnings



% of  
Sales

32.7%

33.8%

Growth rates as compared to same period in prior year.

Adjusted operating income measures the results of the company's operations without certain items that pertain only to the period presented. Management believes this measure is an important measure of the company's operations because it provides investors with a clearer picture of the core operations of the company. This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.

**Alcon**<sup>®</sup>



# Raising 2010 Full Year Adjusted EPS Guidance

- Organic growth in the high single digits

- Diluted earnings per share:

Adjusted EPS guidance **\$7.58 - \$7.68**

- ***Includes on-going U.S. health care reform costs***
  - *\$20 million full-year sales impact*
  - *\$0.06 full-year diluted EPS impact*
- ***Project and deal timing will raise R&D spending versus Q3 2010***
- ***Excludes:***
  - *\$21 million after-tax benefit related to a change in estimate for accrued royalties*
  - *\$25 million tax charge due to loss of U.S. deductibility of retiree medical benefits as a result of U.S. health care reform*
  - *Costs related to change of majority ownership to and/or merger with Novartis*
- ***Assumes retroactive renewal of R&E tax credit in Q410***

Organic sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years.

**Alcon**<sup>®</sup>



## Third Quarter 2010 Webcast

October 21, 2010

# Non-GAAP Reconciliations

ALCON, INC. AND SUBSIDIARIES  
Reconciliation of Non-GAAP Financial Measures  
(in millions, except per share data)

Operating Income				
	Q3 2010	Q3 2009	Growth %	Q3 2010 % of Sales
As Reported	\$ 495	\$ 578	-14.4%	28.1%
Change-in-Control Expenses	133	--		
As Adjusted	<u>\$ 628</u>	<u>\$ 578</u>	8.7	35.7
Net Earnings				
	Q3 2010	Q3 2009	Growth %	
As Reported	\$ 446	\$ 515	-13.4%	
Change-in-Control Expenses	113	--		
As Adjusted	<u>\$ 559</u>	<u>\$ 515</u>	8.5	
Diluted EPS				
	Q3 2010	Q3 2009	Growth %	
As Reported	\$ 1.47	\$ 1.71	-14.0%	
Change-in-Control Expenses	0.37	--		
As Adjusted	<u>\$ 1.84</u>	<u>\$ 1.71</u>	7.6	

Note: Adjusted operating income, net earnings and adjusted diluted EPS measure the results of the company's operations without certain items that did not pertain to the comparable period. Management believes these measures are an important measure of the company's operations because they provide investors with a clearer picture of the core operations of the company. These measures are considered non-GAAP financial measures as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.

# Non-GAAP Reconciliations

ALCON, INC. AND SUBSIDIARIES  
Reconciliation of Non-GAAP Financial Measures  
(in millions, except per share data)

	Operating Income			
	YTD 2010	Q3 2009	Growth %	YTD 2010 % of Sales
As Reported	\$ 1,899	\$ 1,724	10.2%	35.4%
Change-in-Control Expenses	141	--		
Change in Royalty Adjustment	(24)	--		
Reduction in Force	--	19		
As Adjusted	<u>\$ 2,016</u>	<u>\$ 1,743</u>	15.7	37.6

	Net Earnings		
	YTD 2010	Q3 2009	Growth %
As Reported	\$ 1,689	\$ 1,549	9.0%
Change-in-Control Expenses	121	--	
Change in Royalty Adjustment	(21)	--	
U.S. Healthcare Reform *	26	--	
Reduction in Force	--	14	
As Adjusted	<u>\$ 1,815</u>	<u>\$ 1,563</u>	16.1

Note: Adjusted operating income and net earnings measure the results of the company's operations without certain items that did not pertain to the comparable period. Management believes these measures are an important measure of the company's operations because they provide investors with a clearer picture of the core operations of the company. These measures are considered non-GAAP financial measures as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.

\* Related to a change in the tax treatment of retiree medical benefits in the United States.

# Non-GAAP Reconciliations

## ALCON, INC. AND SUBSIDIARIES Reconciliation of Non-GAAP Financial Measures (in millions, except per share data)

	Diluted EPS		
	YTD 2010	Q3 2009	Growth %
As Reported	\$ 5.56	\$ 5.15	8.0%
Change-in-Control Expenses	0.40	--	
Change in Royalty Adjustment	(0.08)	--	
U.S. Healthcare Reform *	0.09	--	
Reduction in Force	--	0.05	
As Adjusted	<u>\$ 5.97</u>	<u>\$ 5.20</u>	14.8

Note: Adjusted diluted EPS measures the results of the company's operations without certain items that did not pertain to the comparable period. Management believes this measure is an important measure of the company's operations because it provides investors with a clearer picture of the core operations of the company. This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.

\* Related to a change in the tax treatment of retiree medical benefits in the United States.

# Non-GAAP Reconciliations

## ALCON, INC. AND SUBSIDIARIES Reconciliation of Non-GAAP Financial Measures

<u>Total Global Sales</u>	<u>Reported Change</u>	<u>Foreign Currency Change</u>	<u>Acquisition Change</u>	<u>Organic Change</u>
<b>Q1 2009</b>	(2.8) %	(7.6) %	-- %	4.8 %
<b>Q2 2009</b>	(3.4)	(6.7)	--	3.3
<b>Q3 2009</b>	5.9	(3.1)	--	9.0
<b>Q4 2009</b>	14.5	6.0	--	8.5
<b>Q1 2010</b>	15.3	5.5	0.2	9.6
<b>Q2 2010</b>	12.5	0.8	0.4	11.3
<b>Q3 2010</b>	9.0	(0.4)	0.7	8.7

Note: Organic change presents sales growth without the impact of foreign exchange fluctuations and acquisitions. Management believes organic sales change is an important measure of the company's operations because it provides investors with a clearer picture of the core rate of sales growth due to changes in unit volumes and local currency prices. This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.

# Non-GAAP Reconciliations

## ALCON, INC. AND SUBSIDIARIES Reconciliation of Non-GAAP Financial Measures (in millions)

	Three Months Ended September 30,		Change	Foreign Currency Change	Acquisition Change	Organic Change
	2010	2009				
<b>Sales by Product Line:</b>						
Pharmaceutical	\$ 758	\$ 659	15.0%	(0.8)%	1.6%	14.2%
Surgical	767	739	3.8	(0.1)	0.2	3.7
Consumer Eye Care	235	216	8.8	--	--	8.8
<b>Total Global Sales</b>	<b>\$ 1,760</b>	<b>\$ 1,614</b>	<b>9.0</b>	<b>(0.4)</b>	<b>0.7</b>	<b>8.7</b>

	Three Months Ended September 30,		Change	Foreign Currency Change	Acquisition Change	Organic Change
	2010	2009				
<b>Sales by Geography:</b>						
United States	\$ 803	\$ 733	9.5%	--%	1.6%	7.9%
Developed international	600	584	2.7	(1.6)	--	4.3
Emerging markets	357	297	20.2	1.0	--	19.2
<b>Total Global Sales</b>	<b>\$ 1,760</b>	<b>\$ 1,614</b>	<b>9.0</b>	<b>(0.4)</b>	<b>0.7</b>	<b>8.7</b>

Note: Organic change calculates sales growth without the impact of foreign exchange fluctuations and acquisitions. Management believes organic sales change is an important measure of the company's operations because it provides investors with a clearer picture of the core rate of sales growth due to changes in unit volumes and local currency prices. This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission. Certain reclassifications have been made to prior year amounts to conform to current year presentation.

# Non-GAAP Reconciliations

## ALCON, INC. AND SUBSIDIARIES Reconciliation of Non-GAAP Financial Measures

<u>Developed International Sales</u>	<u>Reported Change</u>		<u>Foreign Currency Change</u>		<u>Acquisition Change</u>		<u>Organic Change</u>	
2006	8.6	%	0.1	%	--	%	8.5	%
2007	19.9		7.5		0.8		11.6	
2008	18.0		6.7		2.8		8.5	
2009	3.7		(3.2)		--		6.9	
YTD Q3 2010	8.0		2.3		0.1		5.6	

<u>Emerging Market Sales</u>	<u>Reported Change</u>		<u>Foreign Currency Change</u>		<u>Acquisition Change</u>		<u>Organic Change</u>	
2006	21.0	%	2.2	%	--	%	18.8	%
2007	21.3		5.2		--		16.1	
2008	21.5		3.4		--		18.1	
2009	1.0		(10.2)		--		11.2	
YTD Q3 2010	24.3		5.6		--		18.7	

Note: Organic change presents sales growth without the impact of foreign exchange fluctuations and acquisitions. Management believes organic sales change is an important measure of the company's operations because it provides investors with a clearer picture of the core rate of sales growth due to changes in unit volumes and local currency prices. This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.



# Non-GAAP Reconciliations

## ALCON, INC. AND SUBSIDIARIES Reconciliation of Non-GAAP Financial Measures

<u>Q3 2010 Sales</u>	<u>Reported Change</u>		<u>Foreign Currency Change</u>		<u>Acquisition Change</u>		<u>Organic Change</u>	
Emerging markets	20.2	%	1.0	%	--	%	19.2	%
Advanced technology intraocular lenses	13.5		(0.1)		--		13.6	
<u>YTD 2010 Sales</u>	<u>Reported Change</u>		<u>Foreign Currency Change</u>		<u>Acquisition Change</u>		<u>Organic Change</u>	
Total Global Sales	12.2	%	1.9	%	0.4	%	9.9	%

Note: Organic change presents sales growth without the impact of foreign exchange fluctuations and acquisitions. Management believes organic sales change is an important measure of the company's operations because it provides investors with a clearer picture of the core rate of sales growth due to changes in unit volumes and local currency prices. This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.